NOVARTIS CCNP520A2202J
Back to Drug Development Trials
![]()
Drug Development Trials
About the NOVARTIS CCNP520A2202J trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (AD).
